TrialEuropean journal of drug metabolism and pharmacokinetics2022

An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton's Tyrosine Kinase Inhibitor.

Yiming Cheng et al.PubMed ↗Publisher ↗

No numbers read from the abstract.